CSIMarket


Abbvie inc   (ABBV)
Other Ticker:  
 


 

Abbvie inc

ABBV's Financial Statements and Analysis



Abbvie inc reported in the forth quarter of 2023 net earnings per share of $0.46 a decrease by -66.54 % year on year from $1.39 and decline of -53.53 % from $1.00 earned in III. Quarter (Sep 30 2023).


forth quarter of 2023
Earnings Per Share Revenues
$ 0.46 $  14,301 Mill
$-0.93     -66.54 % $-820M     -5.42 %



Abbvie Inc 's Revenue fell by -5.42 % in forth quarter of 2023 (Dec 31 2023) year on year, to $14,301 million and advanced by 2.69 % sequentially.


Abbvie Inc is

More on ABBV's Income Statement



Abbvie Inc 's net income of $824.000 million in the forth quarter of 2023 decreased by -66.67 % from net earnings of $2,472.000 million achieved in IV. Quarter a year ago.

Sequentially net earnings fell by -53.73 % from net income of $1,781.000 million realized in previous quarter.

More on ABBV's Growth

Abbvie Inc Inventories
Inventories grew by 14.53 % to $4,099 million from IV. Quarter a year ago, sequentially inventories rose by 2.96 %. In Dec 31 2023 company's net cash and cash equivalents decreased by $-473 million, capital expenditures grew by -213-3.76%, to $-205 millions compare to same quarter a year ago

More on ABBV's Cash flow Statement


Abbvie inc payed out dividend of $5.93 per share in last 52 weeks representing 217.22 % of net earning per share in trailing twelve-month period.

During the same period Abbvie inc earned $ 12.77 cash per share, on a free-cash flow basis 467.93 % of net earning per share.

Book value fell by -15.09 % sequentially to $5.82 per share.
Tangible Book value grew to $ -43.35 per share from $ -44.36.

Company issued 16.87 million shares or 0.95 % in Dec 31 2023.
Interest Coverage Ratio was 4.71. Debt Coverage Ratio was 0.13.

More on ABBV's Dividends

 Market Capitalization (Millions) 319,117
 Shares Outstanding (Millions) 1,788
 Total Debt (Millions $) 59,385
 Revenue (TTM) (Millions $) 54,318
 Net Income (TTM) (Millions $) 4,873
 Cash Flow (TTM) (Millions $) 3,613
 Capital Exp. (TTM) (Millions $) -777
 Dividend TTM ($) 5.93 $
 Dividend Yield TTM (%) 3.29 %
 Employees (TTM) $ 50,000




Abbvie inc payed out dividend of $5.93 per share in the last 52 weeks representing 217.22 % of net earning per share in trailing twelve-month period.

During the same period Abbvie inc had $ 12.77 cash flow per share, on a free-cash flow basis 467.93 % of net earning per share.

Book value fell by -15.09 % sequentially to $5.82 per share.
Tangible Book value grew to $ -43.35 per share from $ -44.36.

Company issued 16.87 million shares or 0.95 % in Dec 31 2023.
Interest Coverage Ratio was 4.71. Debt Coverage Ratio was 0.13.

More on ABBV's Balance Sheets

 Market Capitalization (Millions) 319,117
 Shares Outstanding (Millions) 1,788
 Total Debt (Millions $) 59,385
 Revenue (TTM) (Millions $) 54,318
 Net Income (TTM) (Millions $) 4,873
 Cash Flow (TTM) (Millions $) 3,613
 Capital Exp. (TTM) (Millions $) -777
 Dividend TTM ($) 5.93 $
 Dividend Yield TTM (%) 3.29 %
 Employees (TTM) $ 50,000
   


  News about Abbvie inc Earnings

AbbVie Inc. Faces Revenue Decline in Q4 2023 Amidst Healthcare Breakthroughs2.

Amidst the backdrop of a turbulent financial quarter for AbbVie Inc., recent developments in the healthcare sector have emerged as a beacon of hope for patients dealing with hard-to-treat follicular lymphoma. Genmab A/S and AbbVie's innovative bispecific antibody epcoritamab has shown promising results in their ongoing clinical trial, with an overall response rate of 82 percent and a complete response rate of 63 percent. This breakthrough in treatment options is certainly a positive development in the healthcare industry.
However, despite these positive advancements in the healthcare sector, AbbVie Inc. has been facing operational challenges, as evidenced by their recent financial figures. The company re...

Abbvie Inc. Navigates Economic Hurdles as Revenue Dips by a Marginal Rate in the Financial Span Ending Sep 30, 2023



Abbvie Inc, a major player in the Pharmaceutical Preparations sector, recently reported its financial results for the time-frame ending September 30, 2023. The company experienced significant setbacks in key financial performance indicators, including income per share, profits, and revenue. This article aims to interpret these results and discuss the potential implications for AbbVie Inc going forward.
Income Per Share and Profit Declines:
Abbvie Inc encountered a sharp decline in income per share, recording a staggering -54.75% decrease to $1.00 per share compared to $2.21 per share the previous year. Furthermore, profits fell by -12.28% in the preceding quarter, resulting in a decrease fr...

Abbvie Inc's Q2 2023 Results: Surprising Growth in EPS, but Troubling -4.924% Drop in Revenue Raises Concerns for Future Growth



Abbvie Inc, a leading pharmaceutical company, recently released its financial results for the second quarter of 2023. While the company managed to improve its earnings per share (EPS) and income per share, it faced challenges in terms of decreasing revenue and increasing inventories. These results provide interesting insights into the company's current financial standing and leave us wondering about its implications for future growth.
EPS and Income Per Share Improvement:
Despite soft orders in the second quarter, Abbvie Inc saw a substantial increase in EPS, with income per share advancing by an impressive 123.53% to $1.14 per share. This indicates the company's ability to efficiently mana...

Abbvie Inc's Income Plunges by 94.82%: What's Next for the Biopharmaceutical Giant?

Abbvie Inc is a biopharmaceutical company that speci...


Date modified: 2024-02-21T12:06:42+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com